Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trial

Fundamental and Clinical Pharmacology

Volumn 23, Issue 4, 2009, Pages 491-500

  Duval, Xavier ^a,b,h   Mentré, France ^a,b,h   Rey, Elisabeth ^a   Auleley, Solange ^a,b,h   Peytavin, Gilles ^a   Biour, Michel ^c   Métro, Annie ^d   Goujard, Cecile ^e   Taburet, Anne Marie ^e   Lascoux, Cecile ^f   Panhard, Xaviere ^a,b,h   Tréluyer, Jean Marc ^a   Salmon Céron, Dominique ^g  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Agence Natl de Rech Sur le SIDA   (France)

^e BICÊTRE HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Hôpital Bicêtre ^*  (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Concentration; HIV 1; Indinavir; Lopinavir; Nelfinavir; Protease inhibitor; Therapeutic drug monitoring

Indexed keywords

INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; YOUNG ADULT;

EID: 67649088607     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00693.x     Document Type: Article

References (30)

1. Chene G., Sterne J.A., May M. et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 362 679 686.
2. Duvivier C., Myrto A., Marcelin A.G. et al. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir. Ther. (2003) 8 603 609.
3. Walmsley S., Bernstein B., King M. et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. (2002) 346 2039 2046.
4. Mannheimer S.B., Morse E., Matts J.P. et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J. Acquir. Immune Defic. Syndr. (2006) 43 (Suppl. 1) S41 S47.
5. Duval X., Journot V., Leport C. et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin. Infect. Dis. (2004) 39 248 255.
6. Back D., Gatti G., Fletcher C. et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS (2002) 16 S5 S37.
7. Burger D., Hugen P., Reiss P. et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS (2003) 17 1157 1165.
8. Burger D.M., Hoetelmans R.M., Hugen P.W. et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir. Ther. (1998) 3 215 220.
9. Yeni P. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d'experts, Flammarion Médecine-Sciences, Paris, 2006.
10. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (2005) Available at: http://wwwaidsinfonihgov/guidelines (accessed on 6 April 2006).
11. Burger D.M., Hugen P.W., Aarnoutse R.E. et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther. Drug Monit. (2003) 25 73 80.
12. Duval X., Mentre F., Lamotte C. et al. Indinavir plasma concentration and adherence score are codeterminant of early virological response in HIV-infected patients of the APROCO cohort. Ther. Drug Monit. (2005) 27 63 70.
13. Kakuda T.N., Page L.M., Anderson P.L. et al. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob. Agents Chemother. (2001) 45 236 242.
14. Bossi P., Peytavin G., Ait-Mohand H. et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. (2004) 5 352 359.
15. Clevenbergh P., Garraffo R., Durant J., Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS (2002) 16 2311 2315.
16. Best B.M., Goicoechea M., Witt M.D. et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2007) 46 433 442.
17. Khoo S.H., Lloyd J., Dalton M. et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - a randomized controlled trial of therapeutic drug monitoring and adherence support. J. Acquir. Immune Defic. Syndr. (2006) 41 461 467.
18. Torti C., Quiros-Roldan E., Regazzi M. et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin. Infect. Dis. (2005) 40 1828 1836.
19. Duval X., Peytavin G., Albert I. et al. Determination of the indinavir and nelfinavir trough plasma concentrations efficacy thresholds according to virological response in human immunodeficiency virus infected patients. HIV Med. (2004) 5 307 313.
20. Acosta E.P., Henry K., Baken L., Page L.M., Fletcher C.V. Indinavir concentrations and antiviral effect. Pharmacotherapy (1999) 19 708 712.
21. Collin F., Chene G., Retout S. et al. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. Ther. Drug Monit. (2007) 29 164 170.
22. Murphy R.L., Brun S., Hicks C. et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 15 F1 F9.
23. Gilbert P.B., DeGruttola V., Hammer S.M., Kuritzkes D.R. Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA (2001) 285 777 784.
24. Begaud B., Evreux J.C., Jouglard J., Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie (1985) 40 111 118.
25. Rockstroh J.K., Bergmann F., Wiesel W. et al. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. AIDS (2000) 14 1181 1185.
26. Burger D.M., Hugen P.W., Aarnoutse R.E. et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J. Acquir. Immune Defic. Syndr. (2001) 26 218 224.
27. Carrieri P., Spire B., Duran S. et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2003) 32 38 47.
28. Kurowski M., Kaeser B., Sawyer A., Popescu M., Mrozikiewicz A. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin. Pharmacol. Ther. (2002) 72 123 132.
29. Kaeser B., Charoin J.E., Gerber M. et al. Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. Int. J. Clin. Pharmacol. Ther. (2005) 43 154 162.
30. Nettles R.E., Kieffer T.L., Parsons T. et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin. Infect. Dis. (2006) 42 1189 1196.